- Report
- December 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe
From €1432EUR$1,500USD£1,199GBP
- Report
- February 2024
- 113 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2024
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- April 2022
Global, Europe, United States, ... Global, Europe, United States, Japan
From €2625EUR$2,750USD£2,199GBP
- Report
- December 2021
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- November 2024
Japan, United States, ... Japan, United States, Europe, Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2024
Japan, United States, ... Japan, United States, Europe
From €3340EUR$3,500USD£2,799GBP
The Rubella Test is a type of infectious disease testing used to detect the presence of rubella antibodies in a person's blood. It is used to diagnose rubella infection, as well as to determine if a person has been vaccinated against the virus. The test is typically performed by a healthcare provider, such as a doctor or nurse, and results are usually available within a few days.
The Rubella Test market is a subset of the larger infectious disease testing market, which is estimated to be worth billions of dollars. The market is driven by the need to diagnose and treat infectious diseases, as well as the increasing prevalence of rubella in certain parts of the world.
Some companies in the Rubella Test market include Abbott Laboratories, Becton Dickinson, Bio-Rad Laboratories, Cepheid, and Roche Diagnostics. Show Less Read more